CytomX Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Phone
650.515.3185
Fiscal Year End
1231
EIN
273521219
Financial Overview
FY2025
$99.01M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 18, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 16, 2026 | View on SEC |
| 10-K Annual financial report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Advancing two lead oncology candidates, CX-904 and CX-801, with initial clinical data expected in mid-to-late 2025.
- Proprietary Probody® platform offers a unique approach to targeted cancer therapy, validated by extensive collaborations with major pharmaceutical companies.
Insider Trading
STRONG SELL
4 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.